# Albireo Fundamentals

ALBO | Stock | ## USD 21.78 0.35 1.63% |

Albireo Pharma fundamentals help investors to digest information that contributes to Albireo Pharma's financial success or failures. It also enables traders to predict the movement of Albireo Stock. The fundamental analysis module provides a way to measure Albireo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Albireo Pharma stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Albireo | Select Account or Indicator |

**M**this year, although the value of Consolidated Income will most likely fall to (36.7

**M**).

## Albireo Total Debt Analysis

Albireo Pharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.## Albireo Pharma Total Debt | ## 9.62 Million |

Total Debt | = | Bonds | + | Notes |

## Current Albireo Pharma Total Debt | 20.41 M |

Most of Albireo Pharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Albireo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Albireo Total Debt Historical Pattern

Today, most investors in Albireo Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Albireo Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Albireo Pharma total debt as a starting point in their analysis.

Albireo Pharma Total Debt |

Share

Timeline |

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Compare to competition |

## Albireo Total Debt

## Total Debt | ## 9.62 Million |

Based on the latest financial disclosure, Albireo Pharma has a Total Debt of 20.41

**M**. This is 99.26% lower than that of the Healthcare sector and 93.72% lower than that of the Biotechnology industry. The total debt for all United States stocks is 99.62% higher than that of the company.## Albireo Pharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Albireo Pharma's current stock value. Our valuation model uses many indicators to compare Albireo Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Albireo Pharma competition to find correlations between indicators driving Albireo Pharma's intrinsic value. More Info.Albireo Pharma is rated**second**in number of employees category among related companies. It is rated

**second**in shares owned by insiders category among related companies . The ratio of Number of Employees to Shares Owned by Insiders for Albireo Pharma is about 270.83 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Albireo Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Albireo Pharma's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Albireo Pharma's earnings, one of the primary drivers of an investment's value.

## Albireo Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Albireo Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Albireo Pharma could also be used in its relative valuation, which is a method of valuing Albireo Pharma by comparing valuation metrics of similar companies.Albireo Pharma is currently under evaluation in working capital category among related companies.

## Albireo Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Albireo Pharma from analyzing Albireo Pharma's financial statements. These drivers represent accounts that assess Albireo Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Albireo Pharma's important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (1.11 M) | (1.18 M) | (1.14 M) | (1.19 M) | (261.77 K) | (282.44 K) | |

Revenue Per Employee | 45.0 | 326.67 K | 175.2 K | 92.06 K | 312.15 K | 335.84 K | |

Average Assets | 68.32 M | 199.19 M | 172.87 M | 240.71 M | 266.95 M | 288.03 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (24.21 M) | (41.21 M) | (57.32 M) | (96.07 M) | (19.8 M) | (21.36 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (24.21 M) | (41.21 M) | (57.29 M) | (96.08 M) | (19.82 M) | (21.39 M) | |

Earnings before Tax | (24.2 M) | (46.09 M) | (62.72 M) | (107.63 M) | (34.03 M) | (36.72 M) | |

Average Equity | 60.21 M | 142.23 M | 105.98 M | 148.89 M | 154.69 M | 122.35 M | |

Enterprise Value | 172.22 M | 120.02 M | 179.83 M | 446.4 M | 196.32 M | 165.73 M | |

Free Cash Flow | (23.26 M) | (26.85 M) | (53.46 M) | (101.11 M) | (108.02 M) | (110.87 M) | |

Invested Capital | (5.2 M) | (8.5 M) | (2.96 M) | 1.41 M | 1.34 M | 1.45 M | |

Invested Capital Average | (4.55 M) | (5.73 M) | (3.27 M) | 2.73 M | (872 K) | (940.84 K) | |

Market Capitalization | 227.83 M | 293.62 M | 322.49 M | 715.59 M | 449 M | 357.51 M | |

Tangible Asset Value | 55.96 M | 168.21 M | 147.81 M | 268.35 M | 284.79 M | 307.27 M | |

Working Capital | 47.08 M | 154.82 M | 122.88 M | 236.58 M | 223.58 M | 241.23 M |

## Albireo Fundamentals

Return On Equity | (31.92) % | |||

Return On Asset | (35.52) % | |||

Profit Margin | (70.79) % | |||

Operating Margin | (248.79) % | |||

Current Valuation | 226 M | |||

Shares Outstanding | 19.28 M | |||

Shares Owned by Insiders | 0.48 % | |||

Shares Owned by Institutions | 104.26 % | |||

Number of Shares Shorted | 1.76 M | |||

Price to Earning | (4.16) X | |||

Price to Book | 2.33 X | |||

Price to Sales | 8.32 X | |||

Revenue | 51.22 M | |||

Gross Profit | 39.22 M | |||

EBITDA | (127.04 M) | |||

Net Income | (36.26 M) | |||

Cash and Equivalents | 180.97 M | |||

Cash per Share | 9.23 X | |||

Total Debt | 20.41 M | |||

Debt to Equity | 0.18 % | |||

Current Ratio | 4.49 X | |||

Book Value Per Share | 9.48 X | |||

Cash Flow from Operations | (113.17 M) | |||

Short Ratio | 2.99 X | |||

Earnings Per Share | (6.73) X | |||

Number of Employees | 130 | |||

Beta | 0.8 | |||

Market Capitalization | 426.25 M | |||

Total Asset | 28.87 M | |||

Retained Earnings | (171.75 M) | |||

Working Capital | 26.76 M | |||

Current Asset | 28.84 M | |||

Current Liabilities | 2.07 M | |||

Z Score | -7.2 |

## About Albireo Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Albireo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Albireo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Albireo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | ||

Cost of Revenue | 1.2 M | 1.2 M | |

Revenues | 40.6 M | 43.8 M | |

Revenue to Assets | 0.13 | 0.12 | |

Revenue Per Employee | 312.1 K | 335.8 K |

## Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Insider Screener Now

## Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |

All Next | Launch Module |

## Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.

The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Please continue to Albireo Pharma Piotroski F Score and Albireo Pharma Altman Z Score analysis. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

## Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.

Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital | Go | |

Insider ScreenerFind insiders across different sectors to evaluate their impact on performance | Go | |

Content SyndicationQuickly integrate customizable finance content to your own investment portal | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | Go | |

Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | Go | |

Volatility AnalysisGet historical volatility and risk analysis based on latest market data | Go | |

Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | Go | |

Volatility AnalysisGet historical volatility and risk analysis based on latest market data | Go |

Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 454.3 M | Quarterly Revenue Growth YOY 1.68 | Return On Assets (0.25) | Return On Equity (0.93) |

The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.